A s bstract. An important determinant ofplateletvessel wall interactions is the local balance of production of endothelial prostacyclin (PGI2) and platelet thromboxane (TX) A2, labile eicosanoids with opposing effects on hemostasis. Disputed evidence suggests that plateletderived prostaglandin endoperoxide intermediates may be utilized as substrates for vascular PG12 synthesis. Using several different approaches, we have found that platelets can transfer endoperoxides to cultured endothelial cells for efficient conversion to PGI2, but a reciprocal transfer of endothelial endoperoxides for utilization by platelet thromboxane synthetase does not occur under the same experimental conditions. However, platelets can utilize arachidonic acid released by endothelial cells for lipoxygenase metabolism. We have directly demonstrated the production of [3H]6-keto-PGF1,, (the breakdown product of [3H]PGI2) by aspirin-treated endothelial cells in the presence ofplatelets stimulated with [3H]arachidonic acid. In coincubation experiments using either arachidonate or ionophore A23187 as a stimulus, radioimmunoassay of the net production of arachidonic acid metabolites showed that 6-keto-PGFI,, generation by aspirin-treated endothelial cells in the presence of platelets may actually exceed its generation by uninhibited endothelial cells alone. In functional assays, platelet aggregation was inhibited in the presence of aspirin-treated endothelial cells after stimulation with either arachidonate or ionophore Dr. Schafer is an Established Investigator of the American Heart Association.
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Introduction
Stimulated vascular endothelial cells and circulating platelets release free arachidonic acid from their membrane phospholipid pools and rapidly oxygenate it to form the labile prostaglandin (PG)' endoperoxides, PGG2 and PGH2, via the aspirin-inhibitable enzyme cyclooxygenase. Platelets also oxygenate arachidonic acid to form hydroperoxy-and hydroxy-fatty acids via the lipoxygenase pathway, which is not blocked by aspirin. The endoperoxides ofendothelial cells and platelets serve as substrates for the enzymatic formation of two labile eicosanoids of extremely potent but completely opposing biologic effects, prostacyclin (PG12) and thromboxane (TX) A2 (TXA2). Endothelial PGI2 synthetase converts PGH2 to PG12, which promotes blood fluidity by acting as a vasodilator and inhibitor of platelet aggregation. Platelet thromboxane synthetase converts PGH2 to TXA2, which promotes hemostasis by acting as a vasoconstrictor and inducer of platelet aggregation. The dynamic balance of production ofvascular P0G2 and platelet TXA2 (which are rapidly broken down to their inactive stable metabolites, 6-keto-PGFIa and TXB2, respectively) is an important determinant of the state of platelet-vessel wall interactions and primary hemo-Bunting and associates (6) originally proposed that plateletderived prostaglandin endoperoxides can be transferred to the vessel wall and utilized by endothelial cells as exogenous substrate for PGI2 synthesis. This mechanism could serve to limit platelet aggregation at sites of vascular injury by shifting the balance locally to preferential synthesis of PGI2. Production of vascular PGI2 from platelet-derived endoperoxides has been confirmed by some (7) but not by other (8) (9) (10) laboratories. This study was designed to investigate the intercellular transfer and utilization of arachidonic acid and its metabolites between platelets and endothelial cells. We have examined in detail the transfer ofendoperoxides from platelets to cultured endothelial cells and the possible reverse transfer of endoperoxides from endothelial cells to platelets. The latter phenomenon is potentially of considerable physiologic and pharmacologic importance, because it would tend to offset any platelet-to-endothelial transfer of endoperoxides and could permit continued platelet TXA2 production in aspirin-treated subjects. Endothelial cell cultures. Bovine aortic endothelial cells (BAEC) were isolated from the intimal lining of the thoracic aorta of yearling calves by a modification of published techniques (1 1, 12) and characterized by morphological, immunologic, and biochemical criteria, as previously described (11, 12) . A strain of these cells (11-BAEC) was grown to confluency in Dulbecco's Modified Eagle's Medium (DME) containing 10% calf serum and used in subculture passages 2-25. In experiments requiring aspirin pretreatment ofthe BAEC, cell monolayers were washed three times with fresh DME, incubated with 0.5 mM aspirin in DME at 370 for 1 h, and then washed again with fresh DME.
Methods
Platelet preparations. Venous blood anticoagulated with 13.5% acid citrate dextrose (National Institutes of Health Formula A) was centrifuged at 160 gfor 10 min to obtain platelet-rich plasma (PRP). For preparation of washed platelet suspensions, PRP was adjusted to pH 6.5 with additional acid citrate dextrose, centrifuged at 1,500 g for 10 min, the platelet pellet washed in buffer containing 8 mM Na2HPO4, 2 mM NaH2PO4, 5 mM KCI, 135 mM NaCl, and 10 mM ethylenediaminetetraacetate, pH 7.4, and finally resuspended in a modified Tyrode's buffer containing 130 mM NaCl, 9 mM sodium bicarbonate, 6 mM dextrose, 10 Experiments were also performed to quantitate endothelial and platelet arachidonic acid metabolites, 6-keto-PGFia and TXB2, respectively. Stirred suspensions of the two cell types, with or without aspirin pretreatment in various combinations, were stimulated with either 1 MM ionophore A23187 or 50 ,M sodium arachidonate. After 5 min of incubation at 37°C, reaction mixtures were immediately microfuged in a Beckman microfuge (Beckman Instruments, Inc., Spinco Div., Palo Alto, CA) at 8,700 g for 2 min and supernatants removed for radioimmunoassay of TXB2 and 6-keto-PGF1,.
HPLC. Pooled ethyl acetate extracts of terminated reactions were evaporated under N2, and the samples were injected in 50 Ml ofmethanol into a 4.6 X 250 mm Ultrasphere ODS 5-Mgm reverse-phase HPLC column (Altex Scientific Inc., Berkeley, CA). Separations were performed as previously described (15) , using increasing proportions ofacetonitrile (30.5-95%) in aqueous phosphoric acid (pH 2.0). The flow rate was 1 ml/min. The column was equilibrated at 30.5% acetonitrile for 40 min before reuse. A Beckman model 1 OA single-pump HPLC with a PerkinElmer (Norwalk, CT) LC-75 variable-wavelength spectrophotometer detector was used, and arachidonic acid metabolites were measured by absorbance at 192 nm and collection of 1.0 ml fractions for radioactivity. Nonradioactive standards were run simultaneously; TXB2, prostaglandins Fu,, E2, and D2, and 12-hydroxy-5,8,10,14-eicosatetraenoic acid (12- Radioimmunoassays. After appropriate dilutions, the amount of TXB2 and 6-keto-PGFIa in supernatants of microfuged samples was determined by standard radioimmunoassay with phosphate-gelatin buffer (50 mM potassium biphosphate, 0.14 M sodium chloride, and 0.1% gelatin, pH 7.4), a 1:2,000 dilution of antibody, and 10,000-dpm
[3H]TXB2 or [3H]6-keto-PGFia. After overnight incubation at 4VC, charcoal-coated dextran was used to separate bound from unbound radioactivity. Cross-reactivities of the anti-TXB2 antibody with 6-keto-PGFIG and of the anti-6-keto-PGFI antibody with TXB2 were both <0.1%. The assays are sensitive to 50 pg/ml TXB2 and 200 pg/ml 6-keto-PGFIa, respectively.
Results
In order to examine the ability of endothelial cells to transfer prostaglandin endoperoxides to platelets, monolayers of endothelial cells were labeled with [3H]arachidonic acid, as described in Methods, washed to remove unincorporated [3H]arachidonic acid, and then stimulated with calcium ionophore A23 187 in the presence or absence of aspirin-treated and washed platelet suspensions. Any radioactive products of these reactions, separated by HPLC, must be derived from phospholipid pools of endothelial origin. As shown in Fig. 1 (16, 17) . Under the conditions of this experiment, we found 72% inhibition of endothelial PGI2 synthesis by tranylcypromine, as measured by radioimmunoassay of 6-keto-PGF1,. Aspirin-treated platelets did, however, aggregate comparably in the presence or absence of aspirin-treated endothelial cells in response to thrombin (1 U/ml) or collagen, agents which can stimulate platelet aggregation independent of thromboxane production (data not shown). These studies therefore showed that insufficient, if any, endoperoxides of endothelial origin can be utilized by platelets to induce aggregation when endogenous platelet endoperoxide production is blocked with aspirin.
To provide a more quantitative analysis of the net result of this apparent preferential transfer ofendoperoxides from platelets to endothelial cells, mixed suspensions of endothelial cells and/ or platelets, pretreated with aspirin in various combinations, were stimulated with arachidonate (50 ,M) or ionophore A23 187
(1 gM), and the amount of TXB2 and 6-keto-PGF1, produced was determined by radioimmunoassay. The results are summarized in Table I . As shown in Table I , Section A, endoperoxides from uninhibited platelets were efficiently utilized by aspirin-pretreated endothelial cells for the generation of 6-keto-PGFI,. In fact, in some cases, the amount of 6-keto-PGFia produced by aspirin-treated endothelial cells in the presence of platelets exceeded that produced by uninhibited endothelial cells alone. This effect was observed both with arachidonate and ionophore A23187 as stimuli. In contrast, as shown in Table   I , Section B, there was no evidence for the "reverse" transfer ofendoperoxides from endothelial cells to platelets. production by aspirin-treated platelets in the presence of uninhibited endothelial cells was no greater than the sum of the amounts of TXB2 produced independently by each (Table I , Section B), or by aspirin-treated platelets and aspirin-treated endothelial cells together (data not shown). Again, this effect was observed both with arachidonate and ionophore A23187 as stimuli. Evidence of endothelial-to-platelet endoperoxide transfer was not detected even when the platelet:endothelial cell count ratio was greatly increased to 500:1. Table II reinterprets these data to show the balance of the net production of the two opposing eicosanoids. The ratios of 6-keto-PGF1,,,/TXB2 or TXB2j6-keto-PGFs, produced in response to arachidonate stimulation are indicated. Table II , Section A demonstrates that, at platelet:endothelial cell ratios of 1:1 and 5:1, utilization of platelet-derived endoperoxides by aspirin-treated endothelial cells is so efficient that the balance of production actually favors the synthesis of PGI2 over TXA2. This transfer of platelet-generated endoperoxides to endothelial cells does not occur, however, at the expense of platelet TXB2 production: TXB2 production by platelets in the presence of aspirin-treated endothelial cells is no less than TXB2 production by the same number of platelets alone. In contrast, as shown in Table II , Section B, the failure of endothelial-derived endoperoxides to be utilized by platelets for thromboxane synthesis is reflected in the very low ratios of TXB2/6-keto-PGF1a.
In order to test the possibility that the failure of endoperoxides Balance of net production of 6-keto-PGFIa and TXB2 in response to 50 ,M arachidonate stimulation. Experimental conditions as in Table I . Corresponding values for 6-keto-PGFI, in (A) and for TXB2 in (B) at each cell-cell ratio are listed in Table I. model system, we were unable to demonstrate a reverse transfer process, i.e., from endothelial cells to platelets, under the same experimental conditions. In contrast, arachidonic acid released upon stimulation from endothelial cell membrane phospholipid pools was freely transferred to aspirin-treated platelets and utilized by platelet lipoxygenase for the synthesis of 12-HETE (Fig.  1) . A precedent for intercellular arachidonic acid transfer occurs in monocytes, which can utilize arachidonic acid released by T lymphocytes as substrate for the synthesis of eicosanoids (19). Our finding, which suggests that platelets (and perhaps leukocytes) can utilize endothelial-derived arachidonic acid substrate for the production of lipoxygenase metabolites after chemical or mechanical perturbation of the vessel wall, may represent an important mechanism of vascular stimulation of blood cell arachidonic acid metabolism. We were interested in examining the reciprocal transfer of endoperoxides from endothelial cells to platelets because, if it were operative, this would tend to offset the endothelial utilization of platelet-derived endoperoxides. Furthermore, because aspirin can have differential inhibitory effects on platelet and endothelial cyclooxygenases (20) (21) (22) , such an interaction could theoretically permit continued thromboxane production to occur in subjects treated with aspirin, if vascular cyclooxygenase were not completely blocked. Our finding of an apparently unidirectional endoperoxide transfer was confirmed by several apgenerated by endothelial cells to be utilized by platelets is due to an inability of endothelial-derived endoperoxides to penetrate cell membranes, intact cells, and cells disrupted by freeze-thaw lysis were incubated together in various combinations. As shown in Table III , transfer of endoperoxides from endothelial cells to platelets could not be demonstrated even when either or both cell types were lysed.
Discussion
This study was designed to investigate the regulation ofplateletvessel wall interactions by the intercellular transfer and utilization of arachidonic acid and its metabolites. Our data indicate that cultured endothelial cells are capable of utilizing platelet-derived endoperoxides for PGI2 production very efficiently. In fact, under some circumstances, platelet-dependent PGI2 synthesis by aspirin-treated endothelial cells considerably exceeds the PGI2 synthetic capacity of uninhibited endothelial cells alone (Table  I , Section A). Unlike platelets, which possess a very active cyclooxygenase and can readily convert arachidonic acid to endoperoxides, vascular cyclooxygenase converts arachidonic acid to endoperoxides quite inefficiently (18) . Therefore, endoperoxides transferred from platelets may bypass this rate-limiting step in endogenous endothelial PGI2 synthesis and thus serve to amplify vascular PGI2 production.
Although we found evidence for efficient transfer of endoperoxides from platelets to endothelial cells in our in vitro Production of TXB2, measured by radioimmunoassay, in stirred suspensions of endothelial cells (EC) and aspirin-treated platelets (ASAplt), alone or in mixture. Where indicated, the cells were lysed by sequential freeze-thawing three times in a dry ice-acetone bath. Reactions were carried out with arachidonate stimulation, as described in Marcus et al. (7) . However, the reverse transfer of endothelial-derived endoperoxides to induce the aggregation of aspirin-treated platelets could not be demonstrated. Aggregation did not occur even when PGI2 synthetase was blocked with tranylcypromine in an attempt to shunt endothelial-derived endoperoxides to the aspirin-treated platelets. Finally, we performed our studies using as substrate both exogenous arachidonic acid and endogenous arachidonic acid released from membrane phospholipid pools by the calcium ionophore A23187. The data using these two sources of arachidonic acid were mutually consistent.
The ability of endothelial cells to utilize prostaglandin endoperoxides generated by platelets activated in their vicinity for PGI2 production was initially suggested by Bunting and associates (6) . In these studies, it was found that indomethacin-treated fresh arterial rings, which did not by themselves produce platelet antiaggregatory activity, were able to inhibit platelet aggregation when they were coincubated with PRP (6). Marcus et al. (7) , using cultured endothelial cells, provided support for this model with functional platelet aggregation experiments and also by directly demonstrating the utilization of radiolabeled plateletderived endoperoxides by aspirin-treated endothelial cells. However, these investigators did not examine the possibility of reciprocal utilization of endothelial-derived endoperoxides by platelets. Other groups have failed to demonstrate transfer of endoperoxides from platelets to preparations of vascular tissue or cultured cells (8) (9) (10) , at least without the use of an inhibitor of thromboxane synthetase (8, 10) , and they have concluded that vascular PGI2 synthesis depends exclusively on endogenously generated substrates. Needleman et al. (8) and Hornstra et al. (9) , using intact vascular segments or blood vessel microsomal preparations, found no PGI2 production from plateletderived endoperoxides. Baenziger et al. (10) likewise found no platelet endoperoxide utilization for vascular PGI2 production, determined by bioassay, using aspirin-treated cultured endothelial and smooth muscle cells.
The mechanism of our finding of efficient unidirectional endoperoxide transfer is unclear, but several possibilities must be considered. It has been suggested that prostaglandin endoperoxides are unable to freely penetrate cell membranes (23, 24) . Therefore, the unbalanced utilization of endoperoxides by endothelial cells and platelets could be due to differences in the subcellular localization of the endothelial PGI2 synthetase and platelet thromboxane synthetase enzymes. For example, plateletderived endoperoxide could preferentially reach the endothelial PGI2 synthetase ifit were an ectoenzyme, as has been postulated (24) . However, purified endoperoxides are efficiently converted both by cultured endothelial cells to PGI2 (25) and by platelets to thromboxane (26, 27) . Furthermore, disruption of the endothelial cells and/or platelets by freeze-thaw lysis (Table III) still did not result in detectable platelet thromboxane formation from endothelial-derived endoperoxides.
Two other possible explanations deserve consideration. Endoperoxides are extremely labile in the presence of plasma proteins, specifically albumin (28) . Therefore, it is likely that the transfer ofendoperoxides between platelets and endothelial cells requires direct cell-to-cell contact. During the contact ofa platelet with an endothelial cell, the large difference in surface area between the two cell types (29, 30) would permit proportionally more platelet-derived endoperoxide to penetrate the endothelial cell than in the opposite direction. Most of the endothelialderived endoperoxide would be dissipated into the circulation and avidly bound to plasma proteins. Therefore, the unbalanced transfer ofendoperoxides from platelets to endothelial cells may be a function of the relatively greater surface area of the platelet being in contact with the endothelial cell at any given time than vice versa. However, even when we attempted to use an overwhelming ratio of platelets to endothelial cells (500:1), thus increasing the effective surface area ofcell-to-cell contact, TXB2 production from endothelial-derived endoperoxides still could not be demonstrated (Table I, Section B) .
Finally, the apparent unidirectional transfer ofendoperoxides may be due to the greater efficiency of endothelial PGI2 synthetase to convert endoperoxides to PGI2 than ofplatelet thromboxane synthetase to convert exogenous endoperoxides to TXA2. This is supported by data shown in Table II , which indicate that utilization of platelet-generated endoperoxides by endothelial PGI2 synthetase is so efficient that the balance of production of the opposing eicosanoids favors PGI2 over TXA2 at some cell-cell ratios. Furthermore, this transfer ofplatelet-derived endoperoxides does not occur at the expense of platelet thromboxane production under these experimental conditions. It is possible that platelet endoperoxides are generated in excess of the capacity of thromboxane synthetase to convert them to TXA2. In the absence of endothelial cells, the excess endoperoxides may be rapidly broken down; in the presence of endothelial cells, however, excess endoperoxides are efficiently transferred from the platelets and converted to PGI2 by the efficient PGI2 synthetase.
In summary, we have used different methods to clearly demonstrate the potential for efficient utilization of platelet-derived endoperoxides by endothelial cells for PGI2 production. Furthermore, we have shown that endoperoxide transfer between platelets and endothelial cells is essentially unidirectional under our experimental conditions. The results of this study suggest a model of tightly localized primary hemostasis. Resting intact endothelium may (or may not) tonically produce small amounts of PGI2. Adjacent to injured vascular intima, however, where platelet activation occurs and platelet arachidonic acid metabolism is stimulated, endothelial PGI2 production is enhanced by utilization ofplatelet-derived endoperoxides. Our data suggest that it is possible, in fact, that under physiologic conditions PGI2 synthesis by endothelial cells depends largely on the transfer of endoperoxides from platelets activated at their surface. The resultant platelet inhibitory effect ofthis process may be amplified by the failure ofa reciprocal transfer ofendoperoxides to platelets for use in thromboxane production. Thus, amplified PGI2 synthesis by intact endothelium adjacent to a site ofvascular injury may serve to efficiently localize platelet plug formation.
